Results for tag: "CD3 Antibodies"

The CD3 antibodies market is a segment within the broader field of immune disorders drugs that focuses on the development and commercialization of monoclonal antibodies targeting the CD3 receptor on T cells. CD3 is a complex of proteins that plays a crucial role in the activation and signaling of T cells which are integral to the body's immune response. Therapeutics based on CD3 antibodies are engineered to modulate the immune system in various ways, such as by activating T cells to attack cancer cells or by suppressing their activity to treat autoimmune diseases. The versatility of CD3 antibodies makes them valuable in the treatment of a diverse range of conditions, including organ transplant rejection, multiple sclerosis, and certain types of cancer. Some notable players in the market for CD3 antibodies include Pfizer Inc., which has been involved in developing and distributing immune disorder treatments, and Amgen Inc., known for its innovative biopharmaceutical products. Other companies with active involvement include Johnson & Johnson, with its subsidiary Janssen Pharmaceuticals, as well as Biogen Idec Inc., all of which have made strides in the research and development of drugs that act on T cells via the CD3 receptor. Show Less Read more